Table 4b.
Cervical mucus score (Insler Score, 0–15), simplified slide test, Kisumu, Kenya, 2019.
| Treatment group | |||
|---|---|---|---|
| TFV/LNG IVR (n = 11) | TFV-only IVR (n = 11) | Placebo IVR (n = 5) | |
| Visit 5: Day 14 of 1st menstrual cyclea | |||
| Observations | 10 | 11 | 5 |
| <7 | 6 (60.0%) | 3 (27.3%) | 1 (20.0%) |
| 7–10 | 3 (30.0%) | 5 (45.5%) | 4 (80.0%) |
| Good (>10) | 1 (10.0%) | 3 (27.3%) | 0 (0.0%) |
| Median (IQR) | 6.0 (5.0–8.0) | 9.0 (6.0–11.0) | 9.0 (9.0–10.0) |
| Visit 8: Day 14 of 3rd menstrual cycleb,c | |||
| Observations | 5 | 7 | 4 |
| <7 | 2 (40.0%) | 1 (14.3%) | 2 (50.0%) |
| 7–10 | 3 (60.0%) | 6 (85.7%) | 1 (25.0%) |
| Good (>10) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) |
| Median (IQR) | 7.0 (6.0–8.0) | 9.0 (7.0–10.0) | 6.5 (5.5–10.0) |
TFV, tenofovir; LNG, levonorgestrel; IVR, intravaginal ring; IQR, interquartile range.
a
One woman did not attend Visit 5; percentages are based on 26 participants.
b
Eleven women did not attend Visit 8; percentages are based on 16 participants.
c
Visit 8 for this table includes 12 women attending Visit 8, which was prior to end of treatment (EOT) IVR removal and 4 who attended Visit 9 (EOT IVR removal) at the time of Visit 8 visit window.